2. Immunology/Inflammation Apoptosis
  3. TNF Receptor CD3
  4. Linvoseltamab

Linvoseltamab  (Synonyms: REGN5458)

Cat. No.: HY-P9989 Purity: 99.71%
SDS
COA
Technical Support

Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM).

For research use only. We do not sell to patients.

CAS No. : 2408319-25-3

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Linvoseltamab Featured Recommendations:

Linvoseltamab Related Antibodies

Top Publications Citing Use of Products

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM)[1][2][3].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species

Bispecific

In Vitro

Linvoseltamab (0.1-10 nM, 48 h) activates NFAT signaling in effector cells, increases the expression of T-cell activation marker CD25, and induces cytotoxicity in BCMA-expressing human plasma cells and multiple myeloma (MM) cells, such as NCI-H929 and MOLP-8[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Linvoseltamab Related Antibodies

Cell Viability Assay[3]

Cell Line: NCI-H929 and MOLP-8
Concentration: 0.1-10 nM
Incubation Time: 48 h
Result: Inhibited cell viability of NCI-H929 and MOLP-8.
In Vivo

Linvoseltamab (0.4-4 mg/kg, iv, twice a week for 7 doses) exhibits antitumor activity against multiple myeloma in mouse models[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NCI-H929 or MOLP-8 xenograft mouse models[3]
Dosage: 0.4-4 mg/kg
Administration: iv, twice a week for 7 doses
Result: Inhibited growth of tumor volume.
Clinical Trial
Molecular Weight

145510.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Linvoseltamab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Linvoseltamab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Linvoseltamab2408319-25-3REGN5458REGN 5458REGN-5458TNF ReceptorCD3Tumor Necrosis Factor ReceptorTNFRCluster of differentiation 3bispecificantibodysafety profilerelapsed/refractory multiple myeloma (RRMM) modelNCI-H929MOLP-8Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Linvoseltamab
Cat. No.:
HY-P9989
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.